BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37927288)

  • 1. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
    Trulson I; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
    Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
    Bi H; Yin L; Fang W; Song S; Wu S; Shen J
    Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
    Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
    Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 9. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
    Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
    Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer.
    Pang L; Wang J; Jiang Y; Chen L
    Exp Ther Med; 2013 Aug; 6(2):355-360. PubMed ID: 24137188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
    Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
    Chen Z; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.